Evaluating the Pharmacokinetics and Safety of Miricorilant

nonalcoholic steatohepatitis (nash), metabolic dysfunction-associated steatohepatitis (mash) / nonalcoholic steatohepatitis (nash) with compensated cirrhosis, metabolic dysfunction-associated steatotic liver disease (masld), non-alcoholic fatty liver disease (nafld), nonalcoholic fatty liver disease (nafld), metabolic dysfunction-associated steatohepatitis (mash), metabolic dysfunction-associated steatosis liver disease (masld), interventional, phase1